Jeffrey Norton
Academic Appointments
- Professor - Med Center Line, Surgery - General Surgery
- Member, Stanford Cancer Institute
Key Documents
Contact Information
-
Clinical Offices
Surgical Oncology 875 Blake Wilbur Drive, Clinic F MC 5826 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 736-4167
- Academic Offices
Personal Information Email Tel (650) 498-6606 Tel (650) 498-6000Alternate Contact JoAnn Smithson Administrative Assistant Email Tel Work (650) 498-6606Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Cancer> GI Oncology
- Adrenal Cancer
- Carcinoid Tumors
- Carcinoid Tumors - Endocrinology
- Carcinoid Tumors - Surgery
- Endocrine - Surgery
Scientific Focus
Current Research Interests
Interleukin-12 is a Th1 cytokine. It is important in the cell mediated immune response. We are investigating its role as an anti-tumor cytokine to augment the immune response against cancer. We are planning a human trial.
Clinical Trials
- Not Recruiting Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
- Recruiting Permission to Collect Blood Over Time for Research
- Recruiting Phase II Gemcitabine + Fractionated Stereotactic Radiotherapy for Unresectable Pancreatic Adenocarcinoma
- Not Recruiting Phase I Dose Escalation of Stereotactic Radiosurgical Boost for Locally Advanced Esophageal Cancer
- Not Recruiting Phase I/II PTK787/ZK 222584 and Gemcitabine in Advanced Pancreatic Cancer
Publications
- Hospital readmission after a pancreaticoduodenectomy: an emerging quality metric? HPB (Oxford). 2013; (2): 142-8
- Metabolomic-derived novel cyst fluid biomarkers for pancreatic cysts: glucose and kynurenine. Gastrointest Endosc. 2013
- Preexisting antitumor immunity augments the antitumor effects of chemotherapy. Cancer Immunol Immunother. 2013
- Seventh edition (2010) of the AJCC/UICC staging system for gastric adenocarcinoma: is there room for improvement? Ann Surg Oncol. 2013; (5): 1631-8
- Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford). 2012; (8): 539-47
- Intensity-modulated radiotherapy for pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys. 2012; (4): e595-601
Help
Trial Administration